{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:17:03Z","timestamp":1791123423186,"version":"4.1.0"},"publisher-location":"Cham","reference-count":89,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319121130","type":"print"},{"value":"9783319121147","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T00:00:00Z","timestamp":1417651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T00:00:00Z","timestamp":1417651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-12114-7_10","type":"book-chapter","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T11:32:05Z","timestamp":1417606325000},"page":"221-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prolactin-Induced Prostate Tumorigenesis"],"prefix":"10.1007","author":[{"given":"Lucila","family":"Sackmann-Sala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1210\/endo.140.11.7090","volume":"140","author":"TJ Ahonen","year":"1999","unstructured":"Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT (1999) Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140:5412\u20135421","journal-title":"Endocrinology"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/endo.143.1.8576","volume":"143","author":"TJ Ahonen","year":"2002","unstructured":"Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT (2002) PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143:228\u2013238","journal-title":"Endocrinology"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"27287","DOI":"10.1074\/jbc.M304307200","volume":"278","author":"TJ Ahonen","year":"2003","unstructured":"Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT (2003) Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287\u201327292","journal-title":"J Biol Chem"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0024-3205(86)90447-9","volume":"39","author":"BB Arnetz","year":"1986","unstructured":"Arnetz BB, Lahnborg G, Eneroth P (1986) Age-related differences in the pituitary prolactin response to thyrotropin-releasing hormone. Life Sci 39:135\u2013139","journal-title":"Life Sci"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1530\/ERC-12-0085","volume":"19","author":"DA Barron","year":"2012","unstructured":"Barron DA, Rowley DR (2012) The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 19:R187\u2013R204","journal-title":"Endocr Relat Cancer"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1530\/EJE-11-0076","volume":"165","author":"K Berinder","year":"2011","unstructured":"Berinder K, Akre O, Granath F, Hulting AL (2011) Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 165:209\u2013215","journal-title":"Eur J Endocrinol"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1210\/endo.142.9.8369","volume":"142","author":"S Bernichtein","year":"2001","unstructured":"Bernichtein S, Kinet S, Jeay S, Madern M, Martial JA, Kelly PA, Goffin V (2001) S179D-hPRL, a pseudo-phosphorylated human prolactin analog, is an agonist and not an antagonist. Endocrinology 142:3950\u20133963","journal-title":"Endocrinology"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"35988","DOI":"10.1074\/jbc.M305687200","volume":"278","author":"S Bernichtein","year":"2003","unstructured":"Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V (2003) Development of pure prolactin receptor antagonists. J Biol Chem 278:35988\u201335999","journal-title":"J Biol Chem"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","volume":"19","author":"C Bole-Feysot","year":"1998","unstructured":"Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998) Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 19:225\u2013268","journal-title":"Endocr Rev"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.humpath.2004.09.009","volume":"35","author":"TJ Browne","year":"2004","unstructured":"Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA (2004) Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 35:1462\u20131468","journal-title":"Hum Pathol"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccr.2012.01.005","volume":"21","author":"N Choi","year":"2012","unstructured":"Choi N, Zhang B, Zhang L, Ittmann M, Xin L (2012) Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21:253\u2013265","journal-title":"Cancer Cell"},{"issue":"12","key":"10_CR12","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1210\/en.2013-1476","volume":"154","author":"HR Christensen","year":"2013","unstructured":"Christensen HR, Murawsky MK, Horseman ND, Willson TA, Gregerson KA (2013) Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology 154(12):4777\u20134789","journal-title":"Endocrinology"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2003-032055","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G (2004) Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 89:2770\u20132775","journal-title":"J Clin Endocrinol Metab"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/en.2006-1761","volume":"148","author":"A Dagvadorj","year":"2007","unstructured":"Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT (2007) Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a\/b signaling pathway. Endocrinology 148:3089\u20133101","journal-title":"Endocrinology"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-07-2024","volume":"14","author":"A Dagvadorj","year":"2008","unstructured":"Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT (2008) Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 14:1317\u20131324","journal-title":"Clin Cancer Res"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1078-0432.CCR-12-0138","volume":"19","author":"JS Damiano","year":"2013","unstructured":"Damiano JS, Wasserman E (2013) Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 19:1644\u20131650","journal-title":"Clin Cancer Res"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/1535-7163.MCT-12-0886","volume":"12","author":"JS Damiano","year":"2013","unstructured":"Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA (2013) Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 12:295\u2013305","journal-title":"Mol Cancer Ther"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1210\/en.2003-0415","volume":"144","author":"K Dillner","year":"2003","unstructured":"Dillner K, Kindblom J, Flores-Morales A, Shao R, Tornell J, Norstedt G, Wennbo H (2003) Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 144:4955\u20134966","journal-title":"Endocrinology"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/sj.bjc.6690445","volume":"80","author":"NE Eaton","year":"1999","unstructured":"Eaton NE, Reeves GK, Appleby PN, Key TJ (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80:930\u2013934","journal-title":"Br J Cancer"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pros.2990110304","volume":"11","author":"HF English","year":"1987","unstructured":"English HF, Santen RJ, Isaacs JT (1987) Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229\u2013242","journal-title":"Prostate"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pros.2990170103","volume":"17","author":"RB Franklin","year":"1990","unstructured":"Franklin RB, Costello LC (1990) Prolactin directly stimulates citrate production and mitochondrial aspartate aminotransferase of prostate epithelial cells. Prostate 17:13\u201318","journal-title":"Prostate"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/jnci\/88.16.1118","volume":"88","author":"PH Gann","year":"1996","unstructured":"Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118\u20131126","journal-title":"J Natl Cancer Inst"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/er.2004-0016","volume":"26","author":"V Goffin","year":"2005","unstructured":"Goffin V, Bernichtein S, Touraine P, Kelly PA (2005) Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26:400\u2013422","journal-title":"Endocr Rev"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ncpendmet0270","volume":"2","author":"V Goffin","year":"2006","unstructured":"Goffin V, Touraine P, Culler MD, Kelly PA (2006) Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2:571\u2013581","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrurol.2011.143","volume":"8","author":"V Goffin","year":"2011","unstructured":"Goffin V, Hoang DT, Bogorad RL, Nevalainen MT (2011) Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol 8:597\u2013607","journal-title":"Nat Rev Urol"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1126\/science.1189992","volume":"329","author":"AS Goldstein","year":"2010","unstructured":"Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010a) Identification of a cell of origin for human prostate cancer. Science 329:568\u2013571","journal-title":"Science"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.molonc.2010.06.009","volume":"4","author":"AS Goldstein","year":"2010","unstructured":"Goldstein AS, Stoyanova T, Witte ON (2010b) Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 4:385\u2013396","journal-title":"Mol Oncol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2353\/ajpath.2010.090653","volume":"176","author":"L Gu","year":"2010","unstructured":"Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L, Nevalainen MT (2010a) Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol 176:1959\u20131972","journal-title":"Am J Pathol"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1677\/ERC-09-0328","volume":"17","author":"L Gu","year":"2010","unstructured":"Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT (2010b) Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17:481\u2013493","journal-title":"Endocr Relat Cancer"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1155\/2010\/610974","volume":"33","author":"L Gu","year":"2010","unstructured":"Gu L, Zhu XH, Visakorpi T, Alanen K, Mirtti T, Edmonston TB, Nevalainen MT (2010c) Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer. Anal Cell Pathol (Amst) 33:55\u201359","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-13-0422","volume":"19","author":"L Gu","year":"2013","unstructured":"Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT (2013) Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res 19:5658\u20135674","journal-title":"Clin Cancer Res"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-13-0605","volume":"13","author":"L Gu","year":"2014","unstructured":"Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT (2014) Pharmacologic suppression of JAK1\/2 by JAK1\/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13:1246\u201358","journal-title":"Mol Cancer Ther"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.ajpath.2013.02.044","volume":"182","author":"BR Haddad","year":"2013","unstructured":"Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT (2013) STAT5A\/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol 182:2264\u20132275","journal-title":"Am J Pathol"},{"key":"10_CR34","first-page":"409","volume":"81","author":"ME Harper","year":"1976","unstructured":"Harper ME, Peeling WB, Cowley T, Brownsey BG, Phillips ME, Groom G, Fahmy DR, Griffiths K (1976) Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh) 81:409\u2013426","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10911-008-9072-x","volume":"13","author":"K Huang","year":"2008","unstructured":"Huang K, Ueda E, Chen Y, Walker AM (2008) Paradigm-shifters: phosphorylated prolactin and short prolactin receptors. J Mammary Gland Biol Neoplasia 13:69\u201379","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<144::AID-CNCR24>3.0.CO;2-4","volume":"77","author":"T Janssen","year":"1996","unstructured":"Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC (1996) In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77:144\u2013149","journal-title":"Cancer"},{"key":"10_CR37","first-page":"8757","volume":"63","author":"AV Kazansky","year":"2003","unstructured":"Kazansky AV, Spencer DM, Greenberg NM (2003) Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 63:8757\u20138762","journal-title":"Cancer Res"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/pros.10113","volume":"53","author":"J Kindblom","year":"2002","unstructured":"Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H (2002) Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53:24\u201333","journal-title":"Prostate"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1210\/en.2002-0187","volume":"144","author":"J Kindblom","year":"2003","unstructured":"Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, Wennbo H (2003) Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144:2269\u20132278","journal-title":"Endocrinology"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.biocel.2011.06.007","volume":"43","author":"M Koptyra","year":"2011","unstructured":"Koptyra M, Gupta S, Talati P, Nevalainen MT (2011) Signal transducer and activator of transcription 5a\/b: biomarker and therapeutic target in prostate and breast cancer. Int J Biochem Cell Biol 43:1417\u20131421","journal-title":"Int J Biochem Cell Biol"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"E592","DOI":"10.1073\/pnas.1318157111","volume":"111","author":"OJ Kwon","year":"2014","unstructured":"Kwon OJ, Zhang L, Ittmann MM, Xin L (2014) Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A 111:E592\u2013E600","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0913873107","volume":"107","author":"DA Lawson","year":"2010","unstructured":"Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 107:2610\u20132615","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0002-9440(10)65333-3","volume":"154","author":"I Leav","year":"1999","unstructured":"Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM (1999) Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 154:863\u2013870","journal-title":"Am J Pathol"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-03-3499","volume":"64","author":"H Li","year":"2004","unstructured":"Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT (2004) Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774\u20134782","journal-title":"Cancer Res"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1158\/1078-0432.CCR-05-0562","volume":"11","author":"HZ Li","year":"2005","unstructured":"Li HZ, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT (2005) Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863\u20135868","journal-title":"Clin Cancer Res"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.biocel.2009.11.001","volume":"42","author":"Z Liao","year":"2010","unstructured":"Liao Z, Lutz J, Nevalainen MT (2010) Transcription factor Stat5a\/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol 42:186\u2013192","journal-title":"Int J Biochem Cell Biol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0026-0495(96)90217-6","volume":"45","author":"Y Liu","year":"1996","unstructured":"Liu Y, Costello LC, Franklin RB (1996) Prolactin specifically regulates citrate oxidation and m-aconitase of rat prostate epithelial cells. Metabolism 45:442\u2013449","journal-title":"Metabolism"},{"issue":"5","key":"10_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1210\/me.2013-1349","volume":"28","author":"RJ Marano","year":"2014","unstructured":"Marano RJ,Ben Jonathan N (2014) Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol 28(5):622\u2013633. doi:me20131349","journal-title":"Mol Endocrinol"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1210\/endo.141.1.7239","volume":"141","author":"D Melck","year":"2000","unstructured":"Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141:118\u2013126","journal-title":"Endocrinology"},{"key":"10_CR50","doi-asserted-by":"crossref","unstructured":"Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT (2012) Nuclear Stat5a\/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol","DOI":"10.1016\/j.humpath.2012.06.001"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1023\/A:1022375429083","volume":"5","author":"ME Molitch","year":"2002","unstructured":"Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55\u201365","journal-title":"Pituitary"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jpeds.2010.12.042","volume":"158","author":"K Nadeau","year":"2011","unstructured":"Nadeau K, Hwa V, Rosenfeld RG (2011) STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J Pediatr 158:701\u2013708","journal-title":"J Pediatr"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1210\/endo-129-2-612","volume":"129","author":"MT Nevalainen","year":"1991","unstructured":"Nevalainen MT, Valve EM, Makela SI, Blauer M, Tuohimaa PJ, Harkonen PL (1991) Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 129:612\u2013622","journal-title":"Endocrinology"},{"key":"10_CR54","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1096\/fasebj.11.14.9409549","volume":"11","author":"MT Nevalainen","year":"1997","unstructured":"Nevalainen MT, Valve EM, Ahonen T, Yagi A, Paranko J, Harkonen PL (1997a) Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 11:1297\u20131307","journal-title":"FASEB J"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1172\/JCI119204","volume":"99","author":"MT Nevalainen","year":"1997","unstructured":"Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL (1997b) Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 99:618\u2013627","journal-title":"J Clin Invest"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/labinvest.3780105","volume":"80","author":"MT Nevalainen","year":"2000","unstructured":"Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H (2000) Epithelial defect in prostates of Stat5a-null mice. Lab Invest 80:993\u20131006","journal-title":"Lab Invest"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa1307557","volume":"369","author":"PJ Newey","year":"2013","unstructured":"Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV (2013) Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 369:2012\u20132020","journal-title":"N Engl J Med"},{"key":"10_CR58","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","volume":"44","author":"LA O\u2019Sullivan","year":"2007","unstructured":"O\u2019Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC (2007) Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease. Mol Immunol 44:2497\u20132506","journal-title":"Mol Immunol"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223","journal-title":"N Engl J Med"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1677\/joe.0.171R001","volume":"171","author":"SK Peirce","year":"2001","unstructured":"Peirce SK, Chen WY, Chen WY (2001) Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol 171:R1\u2013R4","journal-title":"J Endocrinol"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pros.2990040302","volume":"4","author":"S Rannikko","year":"1983","unstructured":"Rannikko S, Adlercreutz H (1983) Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4:223\u2013229","journal-title":"Prostate"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1210\/en.2003-0068","volume":"144","author":"FG Robertson","year":"2003","unstructured":"Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Tornell J, Kelly PA, Green J, Ormandy CJ (2003) Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology 144:3196\u20133205","journal-title":"Endocrinology"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1073\/pnas.0911651107","volume":"107","author":"V Rouet","year":"2010","unstructured":"Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA, Goffin V (2010) Local prolactin is a target to prevent expansion of basal\/stem cells in prostate tumors. Proc Natl Acad Sci U S A 107:15199\u201315204","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0302-2838(03)00038-1","volume":"43","author":"A Ruffion","year":"2003","unstructured":"Ruffion A, Al Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PR (2003) The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 43:301\u2013308","journal-title":"Eur Urol"},{"issue":"24, Suppl 3","key":"10_CR65","first-page":"S1","volume":"72","author":"H Rui","year":"2012","unstructured":"Rui H, Utama F E., Yanac A F., Xia G, Peck A R., Liu C, Rosenberg AL, Wagner KU, Yang N (2012) Prolactin-humanized mice: an improved animal recipient for therapy response-testing of patient-derived breast cancer xenotransplants. Cancer Res 72(24, Suppl 3):S1\u20138","journal-title":"Cancer Res"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148","journal-title":"N Engl J Med"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/modpathol.2009.103","volume":"22","author":"S Sanati","year":"2009","unstructured":"Sanati S, Watson MA, Salavaggione AL, Humphrey PA (2009) Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol 22:1273\u20131279","journal-title":"Mod Pathol"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000225401","volume":"37","author":"J Saroff","year":"1980","unstructured":"Saroff J, Kirdani RY, Chu TM, Wajsman Z, Murphy GP (1980) Measurements of prolactin and androgens in patients with prostatic diseases. Oncology 37:46\u201352","journal-title":"Oncology"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187\u20131197","journal-title":"N Engl J Med"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pros.20332","volume":"66","author":"SL Slager","year":"2006","unstructured":"Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK, Wojno KJ, Cooney KA (2006) Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 66:173\u2013179","journal-title":"Prostate"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.1191","volume":"92","author":"P Stattin","year":"2001","unstructured":"Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R (2001) Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer 92:463\u2013465","journal-title":"Int J Cancer"},{"key":"10_CR72","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1210\/endo.139.9.6209","volume":"139","author":"RW Steger","year":"1998","unstructured":"Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND (1998) Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 139:3691\u20133695","journal-title":"Endocrinology"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/pros.2990060204","volume":"6","author":"AJ Syms","year":"1985","unstructured":"Syms AJ, Harper ME, Griffiths K (1985) The effect of prolactin on human BPH epithelial cell proliferation. Prostate 6:145\u2013153","journal-title":"Prostate"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/0008-5472.CAN-07-2972","volume":"68","author":"SH Tan","year":"2008","unstructured":"Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT (2008) Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 68:236\u2013248","journal-title":"Cancer Res"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11\u201322","journal-title":"Cancer Cell"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/pros.21446","volume":"72","author":"LN Thomas","year":"2012","unstructured":"Thomas LN, Morehouse TJ, Too CK (2012) Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate 72:450\u2013460","journal-title":"Prostate"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/pros.22793","volume":"74","author":"LN Thomas","year":"2014","unstructured":"Thomas LN, Merrimen J, Bell DG, Rendon R, Goffin V, Too CK (2014) Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting. Prostate 74:732\u2013742","journal-title":"Prostate"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1677\/joe.1.06560","volume":"188","author":"FE Utama","year":"2006","unstructured":"Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H (2006) Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 188:589\u2013601","journal-title":"J Endocrinol"},{"key":"10_CR79","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1210\/en.2008-1057","volume":"150","author":"FE Utama","year":"2009","unstructured":"Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H (2009) Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 150:1782\u20131790","journal-title":"Endocrinology"},{"key":"10_CR80","doi-asserted-by":"publisher","first-page":"895238","DOI":"10.1155\/2011\/895238","volume":"2011","author":"KC Valkenburg","year":"2011","unstructured":"Valkenburg KC, Williams BO (2011) Mouse models of prostate cancer. Prostate Cancer 2011:895238","journal-title":"Prostate Cancer"},{"key":"10_CR81","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1152\/ajpendo.2001.280.1.E120","volume":"280","author":"F Van Coppenolle","year":"2001","unstructured":"Van Coppenolle F, Slomianny C, Carpentier F, Le B, X, Ahidouch A, Croix D, Legrand G, Dewailly E, Fournier S, Cousse H, Authie D, Raynaud JP, Beauvillain JC, Dupouy JP, Prevarskaya N (2001) Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 280:E120\u2013E129","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10_CR82","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bmj.4.5999.738","volume":"4","author":"M Vekemans","year":"1975","unstructured":"Vekemans M, Robyn C (1975) Influence of age on serum prolactin levels in women and men. Br Med J 4:738\u2013739","journal-title":"Br Med J"},{"key":"10_CR83","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807","journal-title":"N Engl J Med"},{"key":"10_CR84","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1022149300972","volume":"5","author":"SM Webb","year":"2002","unstructured":"Webb SM, Casanueva F, Wass JA (2002) Oncological complications of excess GH in acromegaly. Pituitary 5:21\u201325","journal-title":"Pituitary"},{"key":"10_CR85","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1172\/JCI119820","volume":"100","author":"H Wennbo","year":"1997","unstructured":"Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J (1997a) Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744\u20132751","journal-title":"J Clin Invest"},{"key":"10_CR86","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1210\/endo.138.10.5461","volume":"138","author":"H Wennbo","year":"1997","unstructured":"Wennbo H, Kindblom J, Isaksson OG, Tornell J (1997b) Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138:4410\u20134415","journal-title":"Endocrinology"},{"key":"10_CR87","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/bi034217s","volume":"42","author":"W Wu","year":"2003","unstructured":"Wu W, Coss D, Lorenson MY, Kuo CB, Xu X, Walker AM (2003) Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 42:7561\u20137570","journal-title":"Biochemistry"},{"key":"10_CR88","first-page":"6098","volume":"61","author":"X Xu","year":"2001","unstructured":"Xu X, Kreye E, Kuo CB, Walker AM (2001) A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res 61:6098\u20136104","journal-title":"Cancer Res"},{"key":"10_CR89","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","volume":"8","author":"TA Yap","year":"2011","unstructured":"Yap TA, Zivi A, Omlin A, de Bono JS (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8:597\u2013610","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Advances in Experimental Medicine and Biology","Recent Advances in Prolactin Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-12114-7_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:43:21Z","timestamp":1675259001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-12114-7_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,4]]},"ISBN":["9783319121130","9783319121147"],"references-count":89,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-12114-7_10","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,4]]},"assertion":[{"value":"4 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}